China Biotech Weekly
·3 min read

China Biotech Weekly #3: Ivonescimab BLA Filed — The First China-Originated Bispecific Headed for FDA Approval

BispecificOncologyCDE FilingFDALicensing

This Week's Top Takeaway

Summit Therapeutics has submitted a Biologics License Application (BLA) to the US FDA for ivonescimab — a PD-1/VEGF bispecific antibody developed by Akeso (康方生物) — for the treatment of EGFR-mutant NSCLC after TKI progression. If approved, ivonescimab would be the first China-originated bispecific antibody to reach the US market. The PDUFA target action date, once accepted, would likely fall in late 2026 — making this the most commercially significant China-to-US regulatory event of the year.

BIOSECURE Watch

Status: 🟢 No Change
    No new developments in the second week since enactment. OMB has not yet initiated public-facing activity on the BCC list process. The focus remains on:
  • Congressional 1260H letter to DoD re: WuXi (no DoD response yet)
  • SEC risk factor disclosures continuing: total approximately 5 companies
  • Law firm advisory publications slowing after initial wave

CDE Filing Watch

  • Summit Therapeutics / Akeso (康方生物) submitted BLA for ivonescimab to FDA. CDE had previously approved ivonescimab in China for first-line PD-L1+ NSCLC based on HARMONi-2 results showing superiority over pembrolizumab.
  • BeiGene (百济神州) filed manufacturing supplements for zanubrutinib at its Guangzhou facility. BeiGene's strategy of in-house manufacturing is increasingly relevant as BIOSECURE concerns make CDMO dependencies a risk factor.

Takeaways for BD Teams

  1. Ivonescimab's BLA is a bellwether for China-originated biologics in the US. FDA's handling of this application — review timeline, advisory committee process, manufacturing site inspection approach — will set precedent for every subsequent Chinese biologic seeking US approval.
  1. The PD-1/VEGF bispecific class is now a $20B+ competitive space. Between ivonescimab (Akeso/Summit), BNT-327 (BioNTech/BMS), and Innovent's (信达生物) program, three China-connected assets are competing for the same blockbuster market. BD teams with oncology mandates should be tracking all three.
  1. CDE speed is a real value driver. Ivonescimab's Chinese clinical development was 12-18 months faster than a comparable US-first program would have been. This "China speed premium" is now quantifiable — and it's being priced into deal terms.
China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan

Need a deeper analysis? We provide custom deal evaluations, entity ownership mapping, and BIOSECURE exposure assessments. Get in touch →